Ocular toxicity and cancer chemotherapy

Cancer

Volumn 78, Issue 7, 1996, Pages 1359-1373

  Al Tweigeri, Taher ^a   Nabholtz, Jean Marc ^b   Mackey, John Robert ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

biological therapy; bone marrow transplantation; chemotherapy; eye; hormonal therapy; toxicity; vision

Indexed keywords

ALKALOID; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BUSULFAN; CHLORMETHINE; CHLORMETHINE DERIVATIVE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITHRAMYCIN; MITOMYCIN C; NITROSOUREA DERIVATIVE; PACLITAXEL; PLATINUM COMPLEX; PURINE DERIVATIVE; RETINOID; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG INDUCED DISEASE; EYE DISEASE; EYE TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; EYE DISEASES; HUMANS; VISION;

EID: 0029838649     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961001)78:7<1359::AID-CNCR1>3.0.CO;2-G     Document Type: Review

References (170)

1. Sullivan RD. The treatment of human cancer with intraarterial nitrogen mustard. Cancer 1951;6:121-31.
2. Anderson B, Anderson B. Necrotizing uveitis incident to perfusion of intracranial malignancies with nitrogen mustard and related compounds. Trans Am Ophthalmol Soc 1960; 58:95-104.
3. Fraunfelder FT. Oncolytic agents. In: Fraunfelder FT, Meyer SM, (editors). Drug induced ocular side effects and drug interactions. Philadelphia: Lea & Febiger, 1989:384-407.
4. Bregeat M, Hermans R. Oedema papillaire spontanement criable aucous d'um traitement par le chlorambucil. Bull Soc Beige Ophthalmol 1972;1960:567-69.
5. Kende G, Sirkin SR, Thomas PRM. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer 1979;44:69-71.
6. Jack MK, Hicks JD. Ocular complications of high dose chemoradiotherapy and marrow transplantation. Ann Ophthalmol 1981;13:709-11.
7. Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Am Acad Ophthalmol 1983;90:1-3.
8. Choonara IA, Overend M, Balley CC. Blurring of vision due to ifosfamide (letter). Cancer Chemother Pharmacol 1987; 20:349.
9. Podos SM, Canellos GP. Lens changes in chronic granulocytic leukemia: possible relationship to chemotherapy. Am J Ophthalmol 1969;68:500-4.
10. Podos SM, Canellos GP. Ocular toxicity of busulfan. Am J Ophthalmol 1969;68:500-4.
11. Ravindranathan MP, Paul VJ, Kurlakose EL. Cataract after busulfan treatment. Br Med J 1972;1:218-9.
12. Grimes P, von Sallmann L, Frichette A. Influence of myleran on cell proliferation in the lens epithelium. Invest Ophthalmol Vis Sci 1964,3:566-7.
13. Grimes P, von Sallmann L. Interference with cell proliferation and induction of polyploidy in rat lens epithelium during prolonged myleran treatment. Exp Cell Res 1966;42:265-273.
14. Sidi Y, Douer D, Pinkhas J. Sicca syndrome in a patient with toxic reaction to busulfan. JAMA 1977;238:1951.
15. Oliverio VT. Toxicology and pharmacology of the nitrosureas. Cancer Chemother Rep 1973;4 (Suppl):13-20.
16. Greenberg HS, Ensminger WD, Chandler WF. Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg 1984;61:423-9.
17. Grimson BS, Maheley MS, Dubey HD. Ophthalmic and central nervous system complications following intra-carotid BCNU. J Clin Neuro-Ophthalmol 1981;1:261-4.
18. Shingleton BJ, Bienfang DC, Albert DM. Ocular toxicity associated with high dose carmustine. Arch Ophthalmol 1982; 100:1766-72.
19. Louic AC, Turrisi AT, Muggia FM. Visual abnormalities fol lowing nitrosourea treatment. Med Pediatr Oncol 1978; 5:245-7.
20. Lokich J, Skarin A, Frei E. Methyl CCNU and adriamycin combination therapy. Cancer 1974;34:1593-7.
21. Gebarski SS, Greenberg HS, Gabrielson TO. Orbital angiographic changes after intra-carotid BCNU chemotherapy. Am J Neuroradiol 1984;5:55-8.
22. Miller DF, Bay JW, Lederman RJ. Ocular and orbital toxicity following intra-carotid injection of BCNU and cisplatin for malignant gliomas. Ophthalmology 1985;92:402-6.
23. Kapp JP, Vance R, Parker JL, Smith RR. Limitations of high dose intra-arterial BCNU chemotherapy for malignant gliomas. Neurosurgery 1982;10:715-9.
24. McLennan R, Taylor HR. Optic neuroretinitis in association with BCNU and procarbazine therapy. Med Pediatr Oncol 1978;4:43-8.
25. Chrousos GA, Oldfield ED, Doppman JL. Prevention of ocular toxicity of BCNU with supraophthalmic intra-carotid infusion. Ophthalmology 1986;93:1471-3.
26. Foo SH, Chol IS, Berenstein A. Supraophthalmic intra-carotid infusion of BCNU for malignant glioma. Neurology 1986;36:1437-44.
27. Shirmamura Y, Chikama M, Tanimoto Y, Kawakami Y, Tsutsumi A. Optic nerve degeneration caused by supraopthalmic carotid artery infusion with cisplatin and nitrosourea. J Neurosurg 1990;72:285-8.
28. Becher R, Schutt P, Osleka R. Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiamminoplatinum. J Cancer Res Clin Oncol 1980;96:219-21.
29. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cisplatin therapy in a thirty year old man. Cancer 1980;45:764-6.
30. Bonadonna G, Brusamolino E, Valagussa P. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
31. Caruso R, Wilding G, Ballintine E, Ozols R. Cisplatin retinopathy. Invest Ophthalmol Vis Sci 1985;26:34.
32. Cohen RJ, Cuneo RA, Crucigar MP. Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatin, vinblastine and bleomycin. J Clin Oncol 1983;1:392-3.
33. Crispino S, Pissocaro G, Solero CL. Transient left homonymous during treatment of testicular carcinoma with cisplatin, vinblastine and bleomycin. Chemoterapia 1984; 3:337-9.
34. Dimond SB, Rudolph SH, Lubicz SS. Cerebral blindness in association with cisplatin chemotherapy for advanced carcinoma of the fallopian tube. Obstet Gynecol 1982;59:845-65.
35. Ostrow S, Hahn D, Wiemick PH. Ophthalmologic toxicity after cis-dichlorodiamminoplatinum therapy. Cancer Treat Rep 1978;62:1591-4.
36. Pippitt CH, Muss HB, Homesley HD. Cisplatin associated cortical blindness. Gynecol Oncol 1981;12:253-5.
37. Walsh TJ, Clark AW, Parhad IM. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982;39:719-20.
38. Wilding G, Caruso R, Lawrence TS. Retinal toxicity after high dose cisplatin therapy. J Clin Oncol 1985;3:1683-9.
39. Stewart DJ, Wallace S, Feun L. A phase I study of intra-carotid artery infusion of cis-dichlorodiamminoplatinum (II) in patients with recurrent malignant intra-cerebral tumors. Cancer Res 1982;42:2059-62.
40. Curtis EM, Murtagh FR. Ocular and orbital toxicity after intra-carotid cisplatin therapy. Am J Ophthalmol 1993; 116:508-9.
41. Rankin EM, Pitts JE. Ophthalmic toxicity during carboplatin therapy. Ann Oncol 1993;4:337-8.
42. O'Brein MER, Tonge K, Blake P, Moskovic E, Wittshaw E. Cortical blindness associated with high dose carboplatin. Lancet Feb 1992;339:558.
43. Shimada M, Wakaizumi S, Kasubchi Y, Kusunoki T, Nakamura T. Cytosine arabinoside and rosette formation in mouse retina. Nature 1973;246:151-2.
44. Percy DH, Danylchuk KD. Experimental retinal dysplasia due to cytosine arabinoside. Invest Ophthalmol Vis Sci 1977;16:353-64.
45. Hopen G, Mondino BJ, Johnson BL. Corneal toxicity with systemic cytarabine. Am J Ophthalmol 1981;91:500-4.
46. Ritch PS, Hansen RM, Heuer DK. Ocular toxicity from high dose cytosine arabinoside. Cancer 1983;51:430-2.
47. Lass JH, Lazarus HM, Reed MD, Herzig RH. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol 1982;94:617-21.
48. Stentoft J. The toxicity of cytarabine (review). Drug Saf Jan-Feb 1990;5:7-27.
49. Maargileth DA, Poplack DG, Tizzo PA. Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multimodality therapy. Cancer 1977;39:58-61.
50. Christophidis N, Lucas I. Lacrimation and 5-FU (letter). Ann Intern Med 1978;89:574.
51. Hammersley J, Luce JK, Florent TR. Excessive lacrimation from fluorouracil treatment. JAMA 1973;225:747-8.
52. Horio T, Murai T, Ikai K. Photosensitivity due to a fluorouracil derivative. Arch Dermatol 1978;114:1498-1500.
53. Straus DJ, Mausolf FA, Ellerby RA. Cicatricial ectropian secondary to 5-fluorouracil therapy. Med Pediatr Oncol 1977;3:15-9.
54. Sciff SR, Shorr N, Adams T. Surgical treatment of punctal canalicular fibrosis from 5-fluorouracil therapy. Cancer 1985;56:2148-9.
55. Bixenman WW, Nicholls JW, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 1968;83:604-8.
56. Sato Y, Morita M, Takahashi H-O. Combined surgery, radiotherapy and regional chemotherapy in carcinoma of the paranasal sinuses. Cancer 1970;25:571-9.
57. Doroshow JH, Locker GY, Gasterland DE. Ocular irritation from high dose methotrexate therapy: pharmokinetics of drug in the tear film. Cancer 1981;48:2158-62.
58. Fraunfelder FT, Meyer SM. Ocular toxicology. In Duane TD, editor. Clinical ophthalmology. Volume 5. Philadelphia: Harper and Row, 1987:37:5.
59. Johnson DR, Burns RP. Blepharoconjunctivitis associated with cancer chemotherapy. Trans Pac Coasi Oto-Ophthalmol Soc Annu Meet 1965;46:48-9.
60. Fishman ML, Bean SC, Cogan DG. Optic atrophy following prophylatic chemotherapy and cranial radiation for acute lymphocytic leukemia. Am J Ophthalmol 1976;82:571-6.
61. Milly RH, Klein ML, Shults WT. Maculopathy associated with combination chemotherapy and osmotic opening of the blood brain barrier. Am J Ophthalmol 1986;102:626-32.
62. Chun JG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986;70:1225-8.
63. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7:168-72.
64. O'Dwyer PJ, Wagner B, Lleyland-Jones B. Pentostatin for lymphoid malignancies. Ann Intern Med 1988;108:733-43.
65. Grever MR, Slaw MFE, Jacob WF. The biochemical and clinical consequences of 2-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981;57:406-16.
66. Major PP, Agarwal RP, Kufe DW. Clinical pharmacology of deoxycoformycin. Blood 1981;58:91-6.
67. Kefford RF, Fox RM. Deoxycoformycin-induced response in chronic lymphocytic leukemia: deoxycoformycin toxicity in non-replicating lymphocytes. Br J Haematol 1982;50:627-36.
68. Spiers ASD, Ruckdeschel JC, Horton, J. Effectiveness of pentostatin in refractory lymphoid neoplasm. Scand J Haematol 1984;32:130-4.
69. Albert DM, Wong VG, Henderson ES. Ocular complications of vincristine therapy. Arch Ophthalmol 1967;78:709-13.
70. Alexander P. Radiation imitative chemicals. Sci Am 1980;202:99-108.
71. Hansson HA. Retinal changes induced by treatment with vincristine and vinblastine. Doc Ophthalmol 1972;31:65-88.
72. Norton SW, Stockman JA. Unilateral optic neuropathy following vincristine chemotherapy. J Pediatr Ophthalmol Strabismus 1979;16:190-3.
73. Ripps H, Carr RE, Siegel IM. Functional abnormalities in vincristine-induced night blindness. Invest Ophthalmol Vis Sci 1984;25:787-94.
74. Sandler SG, Tobin W, Henderson ES. Vincristine induced neuropathy. A clinical study of fifty leukemic patients. Neurology 1969;19:367-74.
75. Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol 1976;81:146-50.
76. Selawry OS, Hananian J. Vincristine treatment of cancer in children. JAMA 1950;183:741-6.
77. Shurin SB, Rekate HL, Annable W. Optic atrophy induced by vincristine. Pediatrics 1982;70:288-91.
78. Awidi AS. Blindness and vincristine. Ann Intern Med 1980;93:781.
79. Byrd RL, Rohrbaugh TM, Raney RB Jr. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 1981;47:37-40.
80. 2. J Clin Oncol 1994;12:1741-2.
81. Capri G, Munzone E, Tarenzi E, Fulfaro F, Gianni L. Optic nerve disturbances: new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994;86:1099-101.
82. Blum R. An overview of studies with adriamycin in the United States. Cancer Chemother Rev 1975;6:24251.
83. Vizel M, Oster MW. Ocular side effects of cancer chemotherapy. Cancer 1982;49:1999-2002.
84. Voest EE, Neijt JP, Keunen JE, Dekker AW, von Asbeck BS. Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother Pharmacol 1993;31:357-62.
85. Rahl AHS, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol 1988;70:373-81.
86. Mori KS. Studies on ptergium part IV. Treatment of pterglum by mitomycin-C instillation. Nippon Ganka Gakkal Zasshi 1993;601-7.
87. Singh S, Wilson MR, Foster CS. Mitomycin-C eye drops as treatment for pteryglum. Ophthalmology 1988;95:813-21.
88. Fukamachi Y, Hikita N. Ocular complication following pteryglum operation and instillation of mitomycin C. Folia Ophthalmol Jpn 1981;32:197-201.
89. Yamanouchi U, Takaku I, Tsuda N. Scieromalacia presumably due to mitomycin C instillation after pteryglum excision. Jpn J Clin Ophthalmol 1979;33:139-44.
90. Yamanouchi U. A case of scleral calcification due to mitomycin C instillation after pteryglum operation. Folia Ophthalmol Jpn 1978;29:1221-5.
91. Yamanouchi U, Mishima K. Eye lesions due to mitomycin C instillation after pteryglum operation. Folia Ophthalmol Jpn 1967;18:854-61.
92. Rubinfeld RS, Pfister RR, Stein RM. Serious complication of topical mitomycin C. Ophthalmology 1992;99:1647-54.
93. Kalse-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep 1978;62:315-20.
94. Kalse-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy: a clinicopathologic report. Ophthalmology 1981;88:89-93.
95. McKeown CA, Swartz M, Blom J. Tamoxifen retinopathy. Br J Ophthalmol 1981;65:177-9.
96. Vinding T, Nielsen NV. Retinopathy caused by treatment with tamoxifen in low dosage.Acta Ophthalmol (Copenh) 1983;61:45-50.
97. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psllas C, Rempapis J, et al. Clear evidence that long term low dose tamoxifen treatment can induce ocular toxicity. Cancer 1992;69:2961-4.
98. Imperia PS, Lazarus HM, Lass J. Ocular complication of systemic cancer chemotherapy. Surv Ophthalmol 1989;34:209-30.
99. Bernardo G, Redaeill C, Plastina M, Bernardo A, Strada MR, Bottero G, et al. Long term adjuvant therapy with tamoxifen: an evaluation of the ocular toxicity. Proc Annu Meet Am Soc Clin Oncol 1994;13:A225.
100. Heler JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamorifen. Am J Ophthalmol 1994;117:772-5.
101. Ashford AR, Donev I, Tlwarl RP. Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988;61:33-5.
102. David DS, Berkowitz JS. Ocular effects of topical and systemic corticosteroids. Lancet 1969;2:149-51.
103. Cohen BA, Som PM, Haffner PH, Friedman AH. Steroid exophthalmos. J Comput Assist Tomogr 1981;5:907-8.
104. Katz B, Carmody R. Exophthalmos induced by exogenous steroids. J Clin Neuro-Ophathalmol 1986;6:250-3.
105. Slansky HH, Kolbert G, Gartner S. Exophthalmos induced by steroids. Arch Ophthalmol 1967;77:579-81.
106. Goldman H. Cortisone glaucoma. Int Ophthalmol Clin 1966;6:991-1003.
107. Schwartz B. The response of ocular pressure to corticosteroids. Int Ophthalmol Clin 1966;6:929-89.
108. Blhari M, Grossman BJ. Posterior subcapsular cataracts related to long term corticosteroid treatment in children. Am J Dis Child 1968;116:604-8.
109. Black RL, Oglesby RB, von Sallman L, Bunim JJ. Posterior subcapsular cataracts in patients with rheumatoid arthritis. JAMA 1960;174:166-71.
110. Carey RM, Kimball AC, Armstrong D, Toxoplasmosis: Clinical experiences in a cancer hospital. Am J Med 1973;34:30-8.
111. Davidson SI, Rennie IG. Ocular toxicity from systemic drug therapy: an overview of clinically important adverse reactions. Med Toxicol 1986;1:217-24.
112. Vietzke WM, Gelderman AH, Grimley PM. Toxoplasmosis complicating malignancy: experience at the National Cancer Institute. Cancer 1968;21:816-27.
113. Wyhinny GJ, Apple DJ, Guastella FR. Adult cytomegalic inclusion retinitis. Am J Ophthalmol 1973;76:778-81.
114. Braver DA, Richards RD, Good TA. Posterior subcapsular cataracts in steroid treated children. Arch Ophthalmol 1967;77:161.
115. Giles CL, Mason GL, Duff IF. The association of cataract formation and systemic corticosteroid therapy. JAMA 1962; 182:719.
116. Dikshit SK, Avashi PN. Posterior lenticular opacities in children on corticosteroid therapy. Indian J Pediatr 1965;32:93.
117. Forman AR, Loreto JA, Tina LU. Reversibility of corticosteroid-associated cataracts in children with nephrotic syndrome. Am J Ophthalmol 1977;84:75.
118. Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmol 1980;98:1773.
119. Loredo A, Rodriguez RS, Murillo L. Cataract after short term corticosteroid treatment. N Engl J Med 1972;286:160.
120. Rooklin AR, Lampert SI, Jaeger EA. Posterior subcapsular cataracts in steroid requiring asthmatic children. J Allergy Clin Immunol 1979;63:3823.
121. Harris JE, Gruber L. The electrolyte and water balance of the lens. Exp Eye Res 1962;1:372.
122. Kinsey VE. Amino acid transport in the lens. Invest Ophthalmol Vis Sci 1965;4:691.
123. Nielsen NV, Sorensen PN. Glaucoma induced by application of corticosteroids to the periorbital region. Arch Dermatol 1978;114:953-4.
124. Zugerman C. Glaucoma from topically applied corticosteroids. Arch Dermatol 1976;112:1326.
125. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in normal eye. Arch Ophthalmol 1963;70:482.
126. Kupfer C. Pseudofacility in the human eye. Trans Am Ophthalmol Soc 1971;69:383.
127. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 1963;70:482.
128. Francois J. Corticosteriod glaucoma. Ann Ophthalmol 1977; 9:1075.
129. Becher B. Cataracts and topical corticosteroids. Am J Ophthalmol 1964;58:872-3.
130. Edward JE Jr., Foos RY, Montgomerie JZ. Ocular manifestations of candida septicemia: review of seventy-six cases of hematogenous candida endophthalmitis. Medicine 1974; 53:47-53.
131. Sundmark E. The occurrence of posterior subcapsular cataracts in patients on long term systemic corticosteroid therapy. Arch Ophthalmol 1963;41:515.
132. Thygeson P. Criteria of cure in trachoma with special reference to provocative tests. Rev Int Track 1953;30:450.
133. Birge HL. Ocular aspects of mycotic infections.Arch Ophthalmol 1952;47:354.
134. Ivey KJ, Denbesten L. Pseudotumor cerebri associated with corticosteroid therapy in an adult. JAMA 1969;208:1698.
135. Walker AE, Adamklewicz JJ. Pseudotumor cerebri associated with prolonged corticosteroid therapy. JAMA 1964;188:779.
136. Blackman HJ, Peck GL, Olsen TG. Blepharoconjunctivitis: a side effect of 13 cis-retinoic acid therapy for dermatologic diseases. Ophthalmology 1979;86:753-8.
137. Gross EG, Helfgatt MA. Retinoids and the eye. Dermatol Clin 1992;10:521-31.
138. Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985;100:534-7.
139. Viraben R, Mathieu C, Fonton B. Benign Intracranial hypertension during etretinate therapy for mycosis fungoides (letter). J Am Acad Dermatol 1985;13:515-7.
140. Kaise-Kupfer MI, Peck GL, Canuso RC. Abnormal retinal function associated with fenretinide a synthetic retinoid. Arch Ophthalmol 1986;104:69-70.
141. Kingston TP, Lowe NJ, Winston J. Visceral and cutaneous toxicity which occurs during retinamide therapy for psoriasis. Clin Exp Dermatol 1986;11:624-7.
142. Guyer DR, Tledeman J, Yannuzzi L. Interferon associated retinopathy. Arch Ophthalmol 1993;111:350-6.
143. Rubinstein RA, Yanoff M, Albert DM. Thrombocytopenia, anemia, and retinal hemorrhage. Am J Ophthalmol 1968; 65:435-9.
144. Seki K, Itou Y, Nishi Y, Isaka Y. Interferon therapy for type C chronic hepatitis and retinal hemorrhage (in Japanese). Kanzo 1993;34:385.
145. Bauherz G, Soeur M, Lustman F. Oculomotor nerve paralysis induced by alpha II-interferon. Acta Neurol Belg 1990;90:111-4.
146. Farkkila M, Roine R. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984;70:42-6.
147. Yamada H, Mizobuchi K, Isogal Y. Acute onset of ocular complication with interferon. Lancet Apr 1994;343:914.
148. Rieded RR, Schmitta A, Havtman A. Ocular pseudo-myasthenic reaction induced by interferon in AIDS patient. Klinische 1991;69:930-1.
149. Hirst LW, Jabs DA, Tutschka PJ. The eye in bone marrow transplantation I: clinical study.Arch Ophthalmol 1983; 101:580-4.
150. Jabs DA, Hirst LW, Green WR, Tutschka PJ, Santos GW, Beschorner WE. The eye in bone marrow transplantation II: histopatholgy. Arch Ophthalmol 1983;101:585-90.
151. Jack MK, Jack GM, Sale GE, Shulman HM, Sullivan KM. Ocular manifestations of graft versus host disease. Arch Ophthalmol 1983;101:1080-4.
152. Jabs DA, Wingard J, Green WR, Farmer ER, Vogelsang G, Saral R. The eye in bone marrow transplantation III: conjunctival graft vs. host disease. Arch Ophthalmol 1989; 107:1343-8.
153. Jack MK, Hicks JD. Ocular complications in high dose chemotherapy and marrow transplantation. Ann Ophthalmol 1981;13:709-11.
154. Deeg HJ, Flournoy N, Sullivan KM. Cataract after total body irradiation and marrow transplantation: a spring effect of dose fractionation. Int J Radiat Oncol Biol Phys 1984;10:957-64.
155. Bender-Gatze C. Late effects of allogeneic bone marrow transplantation. Pediatrician 1991;18:71-5.
156. Bray LC, Carey PJ, Proctor SJ. Ocular complications of bone marrow transplantation. Br J Ophthalmol 1991;75:611-4.
157. Dunn JP, Jabs DA, Wingard J, Enger C, Vogelsang G, Santos G. The eye in bone marrow transplantation V: cataracts after bone marrow transplantation. Arch Ophthalmol 1993; 11:1367-73.
158. Lopez PF, Sternberg P, Dabbs CK, Volger WR, Crocker I, Kalin NS. Bone marrow transplant retinopathy. Am J Ophthalmol 1991;112:635-46.
159. Gloor B, Gratwohl A, Hahn M, Kretzschmar S, Robert Y, Speck B, et al. Multiple cotton-wool spots following bone marrow transplantation for treatment of acute lymphocytic leukemia. Br J Ophthalmol 1985;69:320-5.
160. Bernauer W, Gratwohl A, Keller A, Dalcker B. Microvasculopathy in the ocular fundus after bone marrow transplantation. Ann Intern Med 1991;115:925-30.
161. Vogler WR, Winton EF, Heffner LT. Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preoperative regimen for bone marrow transplantation. Bone Marrow Transplant 1990;6:405-9.
162. Avery R, Jabs DA, Wingard JR, Vogelsang G, Sanal R, Santos G. Optic disc edema after bone marrow transplantation. Ophthalmology 1991;98:1294-1301.
163. Robertson MJ, Socinski Ma, Solffer RJ. Successful treatment of disseminated fusarium infection after outologous bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant 1991;8:143-5.
164. Harris GJ, Will BR. Orbital aspergillosis: conservative debridement and local amphotericin irrigation. Ophthal Plast Reconstr Surg 1989;5:207-11.
165. Kaulfersch W, Urban C, Hauer C. Successful treatment of CMV retinitis with ganciclovir after allogeneic bone marrow transplantation. Bone Marrow Transplant 1989;4:587-9.
166. Wingard JR, Chen DY, Burns WH. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988;71:1432-7.
167. Jabs DA, Wingard JR, Bustros S, de Miranda P, Saral R, Santos GW. BW B759U for cytomegalovirus retinitis: Intraocular drug penetration. Arch Ophthalmol 1986;104:1436-7.
168. Coskuncan NM, Jabs DA, Dunn JP, Haller JA, Green WR, Vogelsang GB, et al. The eye in bone marrow transplantation VI: retinal complications. Arch Ophthalmol 1994;112:372-9.
169. O'Riordan JM, Fitzsimon S, O'Connor M, McCann SR, et al. Retinal microvascular changes following bone marrow transplantation: the role of cyclosporin. Bone Marrow Transplant 1994;13:101-4.
170. Rubin P, Jaffe GJ, Vredenburgh J, Ross M, Peters WP. Ocular toxicity following high dose chemotherapy and autologous bone marrow (abstract). Proc Annu Meet Am Soc Clin Oncol 1994;13:A388.